Newly developed retatrutide, a combined-action drug targeting equally GLP-1 and GIP receptors, is creating considerable buzz within the medical community. Preliminary clinical trials have demonstrated substantial reductions in body size and gains in physiological markers for individuals with obesity . Researchers believe this ground-breaking appro